Professor Martin Ingelsson’s research is aimed at increasing our understanding of the neurotoxic mechanisms in the brains of people with Alzheimer’s disease (AD) and Parkinson’s disease (PD) and using this knowledge to develop novel therapeutic and diagnostic applications. His research, which has a pronounced translational character, evaluates the use of immunotherapy and gene therapy approaches to target pathogenic protein species in preclinical cell and animal models. His group has spearheaded the development of an immunotherapy protocol against PD, which has been proven to successfully reduce alpha-synuclein pathology in preclinical models. This therapeutic strategy has resulted in a humanized antibody, which is undergoing preclinical development with the aim of reaching the clinical trial stage within two to three years. Moreover, the group has developed a gene-editing protocol for treatment targeting amyloid precursor protein in a familial form of Alzheimer’s disease. This therapy has also been successfully evaluated in preclinical models.